Logo image of CR

CRANE CO (CR) Stock Fundamental Analysis

NYSE:CR - New York Stock Exchange, Inc. - US2244081046 - Common Stock - Currency: USD

178.8  +0.4 (+0.22%)

After market: 178.8 0 (0%)

Fundamental Rating

6

CR gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 128 industry peers in the Machinery industry. CR has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. CR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

In the past year CR was profitable.
In the past year CR had a positive cash flow from operations.
CR had positive earnings in each of the past 5 years.
CR had a positive operating cash flow in 4 of the past 5 years.
CR Yearly Net Income VS EBIT VS OCF VS FCFCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

Looking at the Return On Assets, with a value of 12.85%, CR belongs to the top of the industry, outperforming 89.84% of the companies in the same industry.
CR has a Return On Equity of 19.18%. This is amongst the best in the industry. CR outperforms 80.47% of its industry peers.
CR has a Return On Invested Capital of 14.48%. This is amongst the best in the industry. CR outperforms 83.59% of its industry peers.
The Average Return On Invested Capital over the past 3 years for CR is in line with the industry average of 10.72%.
The last Return On Invested Capital (14.48%) for CR is above the 3 year average (9.11%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 12.85%
ROE 19.18%
ROIC 14.48%
ROA(3y)10.39%
ROA(5y)10.5%
ROE(3y)19.31%
ROE(5y)22.01%
ROIC(3y)9.11%
ROIC(5y)8.41%
CR Yearly ROA, ROE, ROICCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

CR has a Profit Margin of 15.87%. This is amongst the best in the industry. CR outperforms 89.06% of its industry peers.
CR's Profit Margin has improved in the last couple of years.
CR has a Operating Margin of 17.31%. This is amongst the best in the industry. CR outperforms 81.25% of its industry peers.
CR's Operating Margin has improved in the last couple of years.
CR has a Gross Margin of 41.67%. This is in the better half of the industry: CR outperforms 77.34% of its industry peers.
In the last couple of years the Gross Margin of CR has grown nicely.
Industry RankSector Rank
OM 17.31%
PM (TTM) 15.87%
GM 41.67%
OM growth 3Y15.82%
OM growth 5Y3.47%
PM growth 3Y-13.15%
PM growth 5Y27.77%
GM growth 3Y6.84%
GM growth 5Y2.54%
CR Yearly Profit, Operating, Gross MarginsCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CR is still creating some value.
CR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CR has less shares outstanding
Compared to 1 year ago, CR has an improved debt to assets ratio.
CR Yearly Shares OutstandingCR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CR Yearly Total Debt VS Total AssetsCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

CR has an Altman-Z score of 9.43. This indicates that CR is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 9.43, CR belongs to the top of the industry, outperforming 94.53% of the companies in the same industry.
There is no outstanding debt for CR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.94
Altman-Z 9.43
ROIC/WACC1.43
WACC10.11%
CR Yearly LT Debt VS Equity VS FCFCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B

2.3 Liquidity

CR has a Current Ratio of 2.08. This indicates that CR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.08, CR is in line with its industry, outperforming 52.34% of the companies in the same industry.
CR has a Quick Ratio of 1.49. This is a normal value and indicates that CR is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.49, CR is doing good in the industry, outperforming 64.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.08
Quick Ratio 1.49
CR Yearly Current Assets VS Current LiabilitesCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

4

3. Growth

3.1 Past

CR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.41%, which is quite impressive.
CR shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -3.00% yearly.
The Revenue has decreased by -0.67% in the past year.
Measured over the past years, CR shows a decrease in Revenue. The Revenue has been decreasing by -8.28% on average per year.
EPS 1Y (TTM)25.41%
EPS 3Y-8.02%
EPS 5Y-3%
EPS Q2Q%13.93%
Revenue 1Y (TTM)-0.67%
Revenue growth 3Y1.09%
Revenue growth 5Y-8.28%
Sales Q2Q%-1.36%

3.2 Future

The Earnings Per Share is expected to grow by 11.85% on average over the next years. This is quite good.
The Revenue is expected to grow by 6.61% on average over the next years.
EPS Next Y10.51%
EPS Next 2Y12.53%
EPS Next 3Y13.49%
EPS Next 5Y11.85%
Revenue Next Year6.34%
Revenue Next 2Y8.68%
Revenue Next 3Y9.18%
Revenue Next 5Y6.61%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CR Yearly Revenue VS EstimatesCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1B 2B 3B
CR Yearly EPS VS EstimatesCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2 4 6 8

1

4. Valuation

4.1 Price/Earnings Ratio

CR is valuated quite expensively with a Price/Earnings ratio of 33.55.
65.63% of the companies in the same industry are cheaper than CR, based on the Price/Earnings ratio.
CR is valuated rather expensively when we compare the Price/Earnings ratio to 26.35, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 27.36, which means the current valuation is very expensive for CR.
65.63% of the companies in the same industry are cheaper than CR, based on the Price/Forward Earnings ratio.
CR is valuated rather expensively when we compare the Price/Forward Earnings ratio to 22.19, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 33.55
Fwd PE 27.36
CR Price Earnings VS Forward Price EarningsCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CR is valued a bit more expensive than the industry average as 70.31% of the companies are valued more cheaply.
64.06% of the companies in the same industry are cheaper than CR, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 39.3
EV/EBITDA 24.14
CR Per share dataCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CR does not grow enough to justify the current Price/Earnings ratio.
CR has an outstanding profitability rating, which may justify a higher PE ratio.
CR's earnings are expected to grow with 13.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.19
PEG (5Y)N/A
EPS Next 2Y12.53%
EPS Next 3Y13.49%

3

5. Dividend

5.1 Amount

CR has a yearly dividend return of 0.49%, which is pretty low.
CR's Dividend Yield is comparable with the industry average which is at 1.93.
Compared to an average S&P500 Dividend Yield of 2.42, CR's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.49%

5.2 History

The dividend of CR decreases each year by -12.19%.
CR has been paying a dividend for at least 10 years, so it has a reliable track record.
Dividend Growth(5Y)-12.19%
Div Incr Years0
Div Non Decr Years0
CR Yearly Dividends per shareCR Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.5 1 1.5

5.3 Sustainability

CR pays out 14.36% of its income as dividend. This is a sustainable payout ratio.
DP14.36%
EPS Next 2Y12.53%
EPS Next 3Y13.49%
CR Yearly Income VS Free CF VS DividendCR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M
CR Dividend Payout.CR Dividend Payout, showing the Payout Ratio.CR Dividend Payout.PayoutRetained Earnings

CRANE CO

NYSE:CR (6/20/2025, 8:26:55 PM)

After market: 178.8 0 (0%)

178.8

+0.4 (+0.22%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)04-28 2025-04-28/amc
Earnings (Next)07-29 2025-07-29/amc
Inst Owners76.14%
Inst Owner Change0%
Ins Owners0.27%
Ins Owner Change0.55%
Market Cap10.28B
Analysts82.35
Price Target195.87 (9.55%)
Short Float %1.31%
Short Ratio1.93
Dividend
Industry RankSector Rank
Dividend Yield 0.49%
Yearly Dividend0.82
Dividend Growth(5Y)-12.19%
DP14.36%
Div Incr Years0
Div Non Decr Years0
Ex-Date05-30 2025-05-30 (0.23)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.76%
Min EPS beat(2)0.24%
Max EPS beat(2)3.28%
EPS beat(4)4
Avg EPS beat(4)1.71%
Min EPS beat(4)0.24%
Max EPS beat(4)3.28%
EPS beat(8)8
Avg EPS beat(8)6.03%
EPS beat(12)11
Avg EPS beat(12)8.46%
EPS beat(16)15
Avg EPS beat(16)10.95%
Revenue beat(2)0
Avg Revenue beat(2)-1.14%
Min Revenue beat(2)-1.2%
Max Revenue beat(2)-1.07%
Revenue beat(4)0
Avg Revenue beat(4)-1.36%
Min Revenue beat(4)-2.46%
Max Revenue beat(4)-0.71%
Revenue beat(8)2
Avg Revenue beat(8)-1.01%
Revenue beat(12)5
Avg Revenue beat(12)3.19%
Revenue beat(16)7
Avg Revenue beat(16)1.16%
PT rev (1m)5.42%
PT rev (3m)2.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.65%
EPS NY rev (1m)0.98%
EPS NY rev (3m)0.14%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.83%
Revenue NY rev (1m)0.3%
Revenue NY rev (3m)0.86%
Valuation
Industry RankSector Rank
PE 33.55
Fwd PE 27.36
P/S 4.84
P/FCF 39.3
P/OCF 33.9
P/B 5.85
P/tB 11.05
EV/EBITDA 24.14
EPS(TTM)5.33
EY2.98%
EPS(NY)6.53
Fwd EY3.65%
FCF(TTM)4.55
FCFY2.54%
OCF(TTM)5.27
OCFY2.95%
SpS36.93
BVpS30.55
TBVpS16.18
PEG (NY)3.19
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.85%
ROE 19.18%
ROCE 18.73%
ROIC 14.48%
ROICexc 18.61%
ROICexgc 40.56%
OM 17.31%
PM (TTM) 15.87%
GM 41.67%
FCFM 12.32%
ROA(3y)10.39%
ROA(5y)10.5%
ROE(3y)19.31%
ROE(5y)22.01%
ROIC(3y)9.11%
ROIC(5y)8.41%
ROICexc(3y)10.78%
ROICexc(5y)10.01%
ROICexgc(3y)18.74%
ROICexgc(5y)19.36%
ROCE(3y)12.01%
ROCE(5y)11.18%
ROICexcg growth 3Y10.29%
ROICexcg growth 5Y0.39%
ROICexc growth 3Y13.04%
ROICexc growth 5Y6.99%
OM growth 3Y15.82%
OM growth 5Y3.47%
PM growth 3Y-13.15%
PM growth 5Y27.77%
GM growth 3Y6.84%
GM growth 5Y2.54%
F-Score6
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0.94
Debt/EBITDA 0
Cap/Depr 82.41%
Cap/Sales 1.96%
Interest Coverage 16.41
Cash Conversion 72.54%
Profit Quality 77.63%
Current Ratio 2.08
Quick Ratio 1.49
Altman-Z 9.43
F-Score6
WACC10.11%
ROIC/WACC1.43
Cap/Depr(3y)93.58%
Cap/Depr(5y)79.88%
Cap/Sales(3y)1.9%
Cap/Sales(5y)1.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.41%
EPS 3Y-8.02%
EPS 5Y-3%
EPS Q2Q%13.93%
EPS Next Y10.51%
EPS Next 2Y12.53%
EPS Next 3Y13.49%
EPS Next 5Y11.85%
Revenue 1Y (TTM)-0.67%
Revenue growth 3Y1.09%
Revenue growth 5Y-8.28%
Sales Q2Q%-1.36%
Revenue Next Year6.34%
Revenue Next 2Y8.68%
Revenue Next 3Y9.18%
Revenue Next 5Y6.61%
EBIT growth 1Y24.28%
EBIT growth 3Y17.08%
EBIT growth 5Y-5.09%
EBIT Next Year23.98%
EBIT Next 3Y15.27%
EBIT Next 5Y12.57%
FCF growth 1Y151.25%
FCF growth 3Y-20.47%
FCF growth 5Y-6.44%
OCF growth 1Y163.6%
OCF growth 3Y-18.53%
OCF growth 5Y-7.3%